A citation-based method for searching scientific literature

Yien Ning Sophia Wong, Roberta Ferraldeschi, Gerhardt Attard, Johann de Bono. Nat Rev Clin Oncol 2014
Times Cited: 129







List of co-cited articles
832 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
19

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Philip A Watson, Vivek K Arora, Charles L Sawyers. Nat Rev Cancer 2015
754
15

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
13

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
13

Enzalutamide in metastatic prostate cancer before chemotherapy.
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, Yohann Loriot, Cora N Sternberg, Celestia S Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury,[...]. N Engl J Med 2014
12

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
12

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
11

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Davide Prandi, Juan Miguel Mosquera, Matteo Benelli, Loredana Puca, Joanna Cyrta, Clarisse Marotz, Eugenia Giannopoulou, Balabhadrapatruni V S K Chakravarthi, Sooryanarayana Varambally,[...]. Nat Med 2016
862
10

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Ian F Tannock, Ronald de Wit, William R Berry, Jozsef Horti, Anna Pluzanska, Kim N Chi, Stephane Oudard, Christine Théodore, Nicholas D James, Ingela Turesson,[...]. N Engl J Med 2004
10

Prostate cancer.
Gerhardt Attard, Chris Parker, Ros A Eeles, Fritz Schröder, Scott A Tomlins, Ian Tannock, Charles G Drake, Johann S de Bono. Lancet 2016
617
9

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Chris Tran, Samedy Ouk, Nicola J Clegg, Yu Chen, Philip A Watson, Vivek Arora, John Wongvipat, Peter M Smith-Jones, Dongwon Yoo, Andrew Kwon,[...]. Science 2009
9

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
Scott M Dehm, Lucy J Schmidt, Hannelore V Heemers, Robert L Vessella, Donald J Tindall. Cancer Res 2008
622
9

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
Vivek K Arora, Emily Schenkein, Rajmohan Murali, Sumit K Subudhi, John Wongvipat, Minna D Balbas, Neel Shah, Ling Cai, Eleni Efstathiou, Chris Logothetis,[...]. Cell 2013
623
9

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
Manav Korpal, Joshua M Korn, Xueliang Gao, Daniel P Rakiec, David A Ruddy, Shivang Doshi, Jing Yuan, Steve G Kovats, Sunkyu Kim, Vesselina G Cooke,[...]. Cancer Discov 2013
395
9


Androgen receptor in prostate cancer.
Cynthia A Heinlein, Chawnshang Chang. Endocr Rev 2004
8

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
James D Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, Michael Moon, Edna Chow Maneval, Isan Chen, Beatrice Darimont,[...]. Cancer Discov 2013
410
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
7

Integrative genomic profiling of human prostate cancer.
Barry S Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao, Brett S Carver, Vivek K Arora, Poorvi Kaushik, Ethan Cerami, Boris Reva,[...]. Cancer Cell 2010
7

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
R Bruce Montgomery, Elahe A Mostaghel, Robert Vessella, David L Hess, Thomas F Kalhorn, Celestia S Higano, Lawrence D True, Peter S Nelson. Cancer Res 2008
7


Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
7

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Ping Mu, Zeda Zhang, Matteo Benelli, Wouter R Karthaus, Elizabeth Hoover, Chi-Chao Chen, John Wongvipat, Sheng-Yu Ku, Dong Gao, Zhen Cao,[...]. Science 2017
544
7

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Jennifer L Bishop, Daksh Thaper, Sepideh Vahid, Alastair Davies, Kirsi Ketola, Hidetoshi Kuruma, Randy Jama, Ka Mun Nip, Arkhjamil Angeles, Fraser Johnson,[...]. Cancer Discov 2017
198
7

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
7

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Karim Fizazi, Neal Shore, Teuvo L Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss,[...]. N Engl J Med 2019
424
7


Emerging mechanisms of enzalutamide resistance in prostate cancer.
Frank Claessens, Christine Helsen, Stefan Prekovic, Thomas Van den Broeck, Lien Spans, Hendrik Van Poppel, Steven Joniau. Nat Rev Urol 2014
91
6


Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014
650
6

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
David F Penson, Andrew J Armstrong, Raoul Concepcion, Neeraj Agarwal, Carl Olsson, Lawrence Karsh, Curtis Dunshee, Fong Wang, Kenneth Wu, Andrew Krivoshik,[...]. J Clin Oncol 2016
207
6

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Christopher J Sweeney, Yu-Hui Chen, Michael Carducci, Glenn Liu, David F Jarrard, Mario Eisenberger, Yu-Ning Wong, Noah Hahn, Manish Kohli, Matthew M Cooney,[...]. N Engl J Med 2015
6

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
6

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Yingming Li, Siu Chiu Chan, Lucas J Brand, Tae Hyun Hwang, Kevin A T Silverstein, Scott M Dehm. Cancer Res 2013
487
5

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
5

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.
Jichao Qin, Xin Liu, Brian Laffin, Xin Chen, Grace Choy, Collene R Jeter, Tammy Calhoun-Davis, Hangwen Li, Ganesh S Palapattu, Shen Pang,[...]. Cell Stem Cell 2012
230
5

Molecular determinants of resistance to antiandrogen therapy.
Charlie D Chen, Derek S Welsbie, Chris Tran, Sung Hee Baek, Randy Chen, Robert Vessella, Michael G Rosenfeld, Charles L Sawyers. Nat Med 2004
5

lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Peng Gu, Xu Chen, Ruihui Xie, Jinli Han, Weibin Xie, Bo Wang, Wen Dong, Changhao Chen, Meihua Yang, Junyi Jiang,[...]. Mol Ther 2017
125
5

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Anu-Maarit Moilanen, Reetta Riikonen, Riikka Oksala, Laura Ravanti, Eija Aho, Gerd Wohlfahrt, Pirjo S Nykänen, Olli P Törmäkangas, Jorma J Palvimo, Pekka J Kallio. Sci Rep 2015
204
5

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Matthew R Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris A Hadaschik, Julie N Graff, David Olmos, Paul N Mainwaring, Ji Youl Lee, Hiroji Uemura,[...]. N Engl J Med 2018
674
5

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung,[...]. N Engl J Med 2018
549
5

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small,[...]. Lancet Oncol 2015
840
5

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.
Eric G Bluemn, Ilsa M Coleman, Jared M Lucas, Roger T Coleman, Susana Hernandez-Lopez, Robin Tharakan, Daniella Bianchi-Frias, Ruth F Dumpit, Arja Kaipainen, Alexandra N Corella,[...]. Cancer Cell 2017
327
5

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
Sheng Yu Ku, Spencer Rosario, Yanqing Wang, Ping Mu, Mukund Seshadri, Zachary W Goodrich, Maxwell M Goodrich, David P Labbé, Eduardo Cortes Gomez, Jianmin Wang,[...]. Science 2017
548
5

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.
Shusuke Akamatsu, Alexander W Wyatt, Dong Lin, Summer Lysakowski, Fan Zhang, Soojin Kim, Charan Tse, Kendric Wang, Fan Mo, Anne Haegert,[...]. Cell Rep 2015
165
5

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.
Yu Sun, Judith Campisi, Celestia Higano, Tomasz M Beer, Peggy Porter, Ilsa Coleman, Lawrence True, Peter S Nelson. Nat Med 2012
532
5

Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler. Int J Mol Sci 2018
128
5

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
774
5

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
Dominick G A Burton, Maria G Giribaldi, Anisleidys Munoz, Katherine Halvorsen, Asmita Patel, Merce Jorda, Carlos Perez-Stable, Priyamvada Rai. PLoS One 2013
37
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.